Nomination Committe for IDL appointed | IDL Biotech
IDL Biotech

CLOSE MENU

Articles

Latest News

February 2019

Nomination Committe for IDL appointed

IDL Biotechs extra ordinary general meeting held on the 25th October 2018 decided to establish a nomination committee.

The two largest shareholders in terms of votes who wish to participate in the nomination committee were entitled to appoint one member each. The shareholders Leif Pihlqvist with companies and AB Grenspecialisten has appointed Jerker Swanstein and Jens Ismunden.

 

For more information, read the pressrelease here (in swedish)

IDL Biotech förbereder kliniska studier i USA för sitt snabbtest för blåscancer, UBC® Rapid

Under 2019 lämnade IDL Biotech in underlag, en så kallad ”pre-submission request”, till amerikanska FDA (Food and Drug Administration) för att kunna få ett framtida godkännande av UBC® Rapid, bolagets snabbtest för blåscancer. Nu går bolaget vidare och förbereder kliniska studier i USA.

Gunnar Wahlberg appointed as acting CEO

The Board has appointed Gunnar Wahlberg as acting CEO.

IDL Biotech

Skip this intro